NCT07616986Recruiting
LITT for Ultra-early GBM Recurrence
Summary
Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy. LITT offers a minimally invasive alternative that may: * Treat recurrence without delaying RT/CT * Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.
Inclusion criteria
• Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status • ≥18 years of age • CRET • Karnofsky Performance Status (KPS) ≥70 • No contra-indication for radio-chemotherapy • Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern • Able to provide informed consent • No contra-indication for LITT • No pregnancy or active breast-feeding • No known coagulopathy independent of medication • No dissemination or multifocal disease • Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included.
Exclusion criteria
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- No phase (N/A)
- Study type
- Interventional
- Countries
- Switzerland
- Sponsor
- Insel Gruppe AG, University Hospital Bern(Other)
- Protocol no.
- 2025-01709
- Conditions
- Glioblastoma (GBM), Glioblastoma - Category
- Interventions
- Device
Treatments studied
- LITT
Locations · 1
- Bern, SwitzerlandDep. of Neurosurgery, Bern University HospitalRecruiting at this site
In total, worldwide, the only site listed in the registry is recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: June 1, 2026).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
Other identifiers
- 2025 · NIH grant
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.